The study was a multicenter, randomized, double-blind trial that enrolled individuals aged 18 years and older who had histologically or cytologically confirmed and previously untreated ES-SCLC. Patients had a disease measurable by RECIST v1.1 and provided a pretreatment tumor sample. Treatment was randomized 1:1 for up to 4 cycles of etoposide/platinum therapy (either cisplatin or carboplatin) in combination with vibostolimab and pembrolizumab (both 200 mg) every 3 weeks or atezolizumab 1200 mg every 3 weeks. Treatment was followed with either the study combination or atezolizumab until disease progression, unacceptable AEs, intercurrent illness, protocol violation, or investigator/patient decision, according to the study authors.3
The primary end point was OS, with secondary end points including progression-free survival, overall response rate, duration of response, safety, and patient-reported outcomes.3 Merck is expected to share full data from the study at a later date because the analysis is still ongoing.2
About The Study
Trial Name: Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)
ClinicalTrials.gov ID: NCT05224141
Sponsor: Merck Sharp & Dohme LLC
Completion Date (Estimated): June 2027
Currently, there are ongoing phase 3 studies evaluating the combination for lung cancer, including KeyVibe-003, KeyVibe-006, and KeyVibe-007. An external data monitoring committee have not reviewed safety analysis in any study modification. Merck reported that the studies are undergoing comprehensive safety monitoring.1
Merck has several clinical development programs in lung cancer, including the IDeate-Lung02 (NCT06203210), which will be assessing the efficacy and safety of ifinatamab deruxtecan (I-DXd; Daiichi Sankyo) for SCLC. The companies reported that the first patient has been dosed.4
References
1. Merck provides update on phase 3 KeyVibe-008 trial evaluating an investigational fixed-dose combination of vibostolimab and pembrolizumab in patients with extensive-stage small cell lung cancer. News release. August 8, 2024. Accessed August 12, 2024. https://www.businesswire.com/news/home/20240808596399/en
2. Ryan C. Merck Discontinues KeyVibe-008 Trial of Vibostolimab/Pembrolizumab Plus Chemo in ES-SCLC. OncLive. August 8, 2024. Accessed August 12, 2024. https://www.onclive.com/view/merck-discontinues-keyvibe-008-trial-of-vibostolimab-pembrolizumab-plus-chemo-in-es-sclc
3. Sands J, Reck M, Navarrow A, Chiang AC, et al. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal of Clinical Oncology. doi:https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS8606
4. Ferruggia K. New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer. Pharmacy Times. August 9, 2024. Accessed August 12, 2024. https://www.pharmacytimes.com/view/new-study-assesses-ifinatamab-deruxtecan-for-treatment-of-small-cell-lung-cancer